Enliven Therapeutics' ELVN-001: Navigating Competitive Challenges and Opportunities in the CML Market

TipRanksDec 10 13:55 ET

LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsDec 9 08:31 ET · Ratings

JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsDec 5 11:35 ET · Ratings

Strong Buy Recommendation for Enliven Therapeutics: Promising Efficacy and Strategic Positioning in CML Market

TipRanksDec 5 10:27 ET

A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $36 to $40

Moomoo NewsNov 15 08:00 ET · Ratings

Express News | Baird Maintains Outperform on Enliven Therapeutics, Raises Price Target to $40

BenzingaNov 15 07:19 ET